Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma | British Journal of Cancer -…

Posted: March 18, 2022 at 8:26 pm

Sample demographics

Twenty-five participants from across the UK were interviewed who were diagnosed with early-stage melanoma (Stages IAIIC) between 2011 and 2021 (see Table1 for a description of the cohort).

Views from participants regarding ctDNA monitoring for signs of early relapse and early treatment were grouped into two themes: (1) ctDNA monitoring would add service value and (2) test results provide opportunity and knowledge, with each theme including subthemes. All participant names have been replaced with pseudonyms.

The majority of participants did not know what ctDNA monitoring was or were unable to provide a definition. Upon providing participants with a simple definition of the new technology and blood test procedure, all of the participants described regular ctDNA monitoring as a good idea, as the new technology would be more scientific, would reduce the fear of the unknown and identify relapse early.

The majority of participants described skin check procedures as inconsistent in quality. They explained that at each appointment checks would be performed by a different healthcare professional, with some more thorough than others. They felt that skin checks are subject to human error and feared that changes could be missed. Consequently, participants believed that more could be done to provide them with a consistent marker of relapse:

Ive gone from having really detailed full body checks, lymph node checks, et cetera, every single one of the moles and I have a lot of them on my body being checked, to, okay, well check your lymph nodes, well look at the original site, are there any that youre worried about, type thing? (Fiona, 42, stage 1b, diagnosed in 2015)

When presented with the idea of a blood test to detect for early signs of relapse, all participants reacted positively, identifying ctDNA monitoring as the next step in melanoma care:

I think the treatment, as they stand at the moment, is all pretty visual. You know, on the whole, especially for stage 1 and 2, I think its virtually all visual, and things can get missed. Whereas, if youve got definite results, or likely results, from something like a blood test, I believe that to be more the way forward. (Harry, 49, stage 2b, diagnosed in 2017).

Compared to skin checks, they described a blood test as a more scientific measure, providing conclusive evidence of cancer recurrence. They explained that if ctDNA monitoring had been offered as part of their follow-up care, they would have been more reassured, describing the test as an extra safety measure or as one participant described another line of defence (Graeme, 34, stage 2a, diagnosed in 2021):

Id be over the moon if someone said to me, were going to put you on regular checks for x number of years as well as these visual skin checks. It feels more scientific. (Gill, 51, stage 1a, diagnosed in 2019)

As well as mitigating the effects of human error at skin checks, participants explained that blood test monitoring for early signs of relapse would be essential for providing internal evidence of change. Nevertheless, although deemed more conclusive than skin checks, all participants believed that ctDNA monitoring should not replace visual checks but be used alongside them for a belt and braces approach to care:

I just think its like a double check really isnt it, its like a belt and braces, youve got a visual and then youve got the internal and youve got something scientific that can be kind of highlighting you as early as possible. Especially if its being done every three months, thats so quick in terms of, if you start to see something then, you could do something quite preventable. (Yvonne, 47, stage 1b, diagnosed in 2019)

Participants described melanoma as a sneaky disease with no reliable means of knowing whether relapse would occur. This fear of the unknown was identified as anxiety-provoking and hard to live with post-diagnosis. However, the participants explained that a regular blood test would provide them with the confidence and peace of mind that they were being monitored for melanoma relapse more closely:

well certainly me with melanoma, you know, thats absolutely my biggest fear, is that its going to come back and Im not going to know about it, Im not going to know about it until, you know, Im so much further down the line so to speak. So, you know, if anything could detect something early and there could be early intervention then, you know, I would want to have it. (Lisa, 32, stage 2a, diagnosed in 2018)

They suggested that opting for this blood test would enable patients to feel more proactive about their care, reducing anxiety and enabling them to be forewarned about a potential relapse. Similarly, all participants felt that with regular blood tests, the anxieties regarding small changes to the skin and moles that occur between appointments could be better managed due to perceived additional surveillance:

say youre 1A and then finding a lymph node enlarged. That might happen in a second because you might find it and your mind does this massive jump, whereas if you were being monitored youd have a bit of logic. Youd be able to think well, I was monitored however long ago, this could be something else. I think it would just add a kind of reassurance that more than you poking and prodding your own body around. (Louise, 47, stage 1a, diagnosed in 2019)

The majority of participants viewed having regular blood tests for ctDNA monitoring could be useful as an early detection measure for relapse. Although the thought of relapse was difficult to consider, participants felt that a ctDNA test would provide them with the best opportunity to catch recurrence early before presentation with symptoms or radiological detection:

if it can detect something that mightthat wouldnt necessarily get picked up because obviously melanoma travels in the blood and unless youve got something, I dont know, maybe a mole or a lump, or something like that, you would never know until that. But obviously if this could pick that up beforehand then I think it would be a good thing. (Rebecca, 49, stage 1a, diagnosed in 2015)

In addition due to the radiation risks associated with computerising tomography (CT) scans, regular blood tests were deemed more favourable for some participants:

I think a blood test would be better than a scan, in levels of progression you would get your skin check, your blood check and then a scan would be the next step after that Id say. So it saves you having to have unnecessary exposure to radiation and things like that, which obviously is another cause of cancers. (Cathy, 34, stage 1a, diagnosed in 2019)

However, not all participants agreed that early treatment following the detection of ctDNA was appropriate, as a minority questioned whether treatment should be provided only after evidence of a tumour has been found via a CT scan, as they believed treatment prior to the identification of mass could be unnecessary:

Its hard, isnt it, because I think if youve actually got cancer and its there and you know its there, you want to do everything you can to get rid of it, dont you? [] But if its not actually come yet, do you really want treatment that could make you ill? (Jean, 63, stage 1a, diagnosed in 2017)

For the reassurance it would provide a number of participants explained that they would be happy to receive a ctDNA test for the rest of their lives, especially if the frequency of the blood test was manageable:

So if it was every few months, every three months or longer then Id probably be happy for it to go on for longer or indefinitely if need be. (Eric, 39, Stage 2a, diagnosed in 2018)

However, they understood that this might not be possible due to NHS funding, as well as the scientific rationale that the risk of recurrence decreases over time. For ctDNA monitoring to add the most value to patients, the majority explained that monitoring should be more frequent closer to diagnosis and reduced as the risk decreases, identifying a need for a risk-stratified approach:

I suppose it would depend how far after your diagnosis you were and what your dermatologist said were your chances of it recurring. So possibly the same as skin checks where its more frequent in the beginning and maybe spaces out as you get further away from it. (Louise, 47, stage 1a, diagnosed in 2019)

They described that three monthly for three years and 6 monthly for 2 years would be ideal as it would fit in with the existing care structure for stage two patients in the UK. Despite this ideal timeline, all participants stressed the importance of identifying ctDNA in the blood at the earliest opportunity. They, therefore, explained that if ctDNA can be identified earlier or later than three months then the frequency of blood tests should reflect this:

So it would depend on, I guess, the evidence for how likely you would expect to see changes. So if its once a year, six months, three months, I would say yes to whatever people gave me because it sounds like a preventable strategy kind of thing. (Yvonne, 47, stage 1b, diagnosed in 2019)

All participants described waiting and receiving test results as anxiety-provoking regardless of the outcome. They felt that being informed as to when to expect their ctDNA test results would improve anxiety. Notification of a negative test result would provide them with the reassurance to move on with life between tests. A positive test result, although worrying was viewed as an opportunity to access treatment early and receive better health outcomes.

All participants described waiting for test results as an anxious time and a result for a ctDNA blood test would be no exception. Participants identified that until results were received, there is constant speculation about the outcome, with some not being able to relax during the waiting period:

once you have a test for something youve always got it in the back of your mind until the results come in, so I wouldnt be totally on edge all the time, but it would be in [the] back of my head all the time. (Vanessa, 57, stage 2b, diagnosed in 2018)

With result anxiety in mind the majority of participants cited under two weeks as an appropriate time to receive notification of results. Others explained that waiting for their blood test result would depend on laboratory turnaround times in processing blood samples. However, no matter how long results would take, all participants explained that they would require notification of when to expect their results enabling them to manage their anxiety:

if they dont know what timeframe its going to be expected in, some peoples anxiety levels may be really, really high, straight from the off [] Whereas, if they know its not going to be expected for two weeks, a month, then they can at least get on with their lives, and not have it right at the forefront of their thoughts all the time. (Sam, 53, stage 1b, diagnosed in 2015).

Yet some identified that after attending for multiple blood tests receiving results would become routine and less worrying over time:

I dont think I would be particularly thinking about results coming through. I can imagine Id forget about it really over time and a letter or whatever it is would arrive every two months and I wouldnt be anticipating receiving it or anything like that. (Eric, 39, stage 2a, diagnosed in 2018).

When they considered how it would feel to receive ctDNA results, all participants said that they would be happy and trust their result if it were negative. All participants explained that they would want to be notified of a negative test result, as lack of notification would be unacceptable. They argued that they would not accept no news is good news but would instead worry and speculate about their result, with some being prepared to call services directly for confirmation:

I think, if I wasnt notified, Id be wondering if the letter is stuck in the post or if theres some problem at the hospital notifying, or there was an admin error. To have a negative result is much better than to be told if youre positive because it stops you worrying - I just want to check that that was okay and its just that you havent sent it out or I think I, personally, would still ring up about a few weeks later to say just want to check what results are on the file or Id bother my GP for it. (Gill, 51, stage 1a, diagnosed in 2019.)

Participants explained that a simple letter or text message notifying them of a negative result would provide them with peace of mind before their next appointment. Knowledge of a negative test result for ctDNA was viewed as something that could enable patients to move on with their lives between tests, providing them with time to enjoy life and worry less. Specifically, one participant explained that consistent notifications of negative test results would improve their state of mind regarding a potential relapse:

I think as well, the more times that happened [receiving a negative test result], so the further into those five years I got, I would become more and more reassured. You know, at three years, at four years, Id start to be probably quite optimistic. Because, again, I know that most melanoma reoccurs within the first two years. And I know that if you get to five years, you know, its quite a Its a very positive milestone (Graeme, 34, stage 2a, 2021)

However for a minority, the thought of there is always next time would be difficult to ignore, meaning any reassurance gained from a negative test result would be temporary. For example, one participant explained that the level of reassurance a negative test result would provide would depend on when the test was taken during their follow-up, with a negative ctDNA result at the beginning of monitoring being less significant than one received towards the end of follow-up:

I think it depends how long after youve been diagnosed that the test takes place, you know, where you are on your long term journey I suppose. If its, you know, a few months after I think youd be waiting for the next test for something, you know, youd be expecting something else to be happening next time in terms of spread. (Steph, 52, stage 2a, diagnosed in 2018)

Participants explained that a positive ctDNA blood test result would provide them with a chance to be treated early. Although a positive test result is not good news, they would be grateful that relapse was identified before cancer had time to progress and present visually:

Well, obviously thats [a positive result] going to cause a bit more anxiety, isnt it? But also at the same time there could be a bit of a relief there, you know, that its actually been caught rather than it not being picked up. So it can work either way, really. For me, if it was positive, Id rather know. That theres something going on, and maybe we can do something about it. (Jean, 63, stage 1a, diagnosed in 2017)

The majority of participants explained that they would soon deal with the initial shock of a positive test result and instead would concentrate their minds on what needed to be done to reduce the chances of cancer progressing:

Well, the first word that came to my mind was devastated, gutted. But, Id be like, right, okay, its been caught, before it can hopefully get anywhere, like if youre in regular testing? Id think, right, its been caught early, what are we going to do about it? (Cathy, 34, stage 1a, diagnosed in 2019)

As the majority would want to immediately know their management plan, they suggested that information material, such as leaflets and result letters state clearly what a positive test result would mean. Should a positive test result be delivered by letter, participants stressed the importance of having the opportunity to speak with a healthcare professional or have an appointment automatically arranged. Others believed that a positive test result and notification of needing treatment should be delivered in person to enable the patient to ask questions and be provided with the space and time they need to process the information with a healthcare professional present.

See original here:
Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma | British Journal of Cancer -...

Related Posts